JUPITER, FL / Paris, France / September 26, 2023, Dyadic International, Inc. (« Dyadic ») (NASDAQ: DYAI) and bYoRNA SAS (« bYoRNA ») today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA (« mRNA »). Dyadic is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health. bYoRNA is a French biotechnology company focused on producing affordable therapeutic mRNA, at scale, for human and animal health. To know more
